Claims for Patent: 12,358,870

Summary for Patent: 12,358,870

Title:	Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof
Abstract:	Provided herein are solid dispersions comprising a HIF-2α inhibitor, pharmaceutical compositions comprising the solid dispersions, and methods for treating HIF-2α-mediated diseases and conditions.
Inventor(s):	Christopher Lindemann, Peter J. Stengel
Assignee:	Peloton Therapeutics Inc
Application Number:	US17/286,581
Patent Claims:	1. A pharmaceutical solid dosage form for oral delivery of a compound of Formula (I), wherein the solid dosage form comprises a solid dispersion comprising the compound of Formula (I), a pharmaceutically acceptable polymer selected from the group consisting of Hypromellose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), and polyethylene glycol vinyl acetate vinylcaprolactam, one or more pharmaceutically acceptable excipients comprising a binder, a filler, a disintegrant and a lubricant, wherein the binder is a microcrystalline cellulose, and the solid dosage form is a capsule or a tablet. 2. The solid dosage form of claim 1, wherein the solid dosage form is a tablet. 3. The solid dosage form of claim 1, wherein the one or more pharmaceutically acceptable excipients further comprise a glidant. 4. The solid dosage form of claim 1, wherein the solid dispersion is present in an amount from 15% to 50% by weight of the solid dosage form. 5. The solid dosage form of claim 1, wherein the pharmaceutically acceptable polymer is HPMCAS. 6. The solid dosage form of claim 1, wherein the pharmaceutically acceptable polymer is present in an amount from 15% to 35% by weight of the solid dosage form. 7. The solid dosage form of claim 1, wherein the compound of Formula (I) is present in an amount from 1% to 15% by weight of the solid dosage form. 8. The solid dosage form of claim 1, comprising 5 mg to 100 mg of the compound of Formula (I). 9. The solid dosage form of claim 1, comprising about 10 mg of the compound of Formula (I). 10. The solid dosage form of claim 1, comprising about 40 mg of the compound of Formula (I). 11. The pharmaceutical solid dosage form of claim 1, wherein the one or more excipients further comprise mannitol, croscarmellose sodium and magnesium stearate. 12. The pharmaceutical solid dosage form of claim 1, wherein the pharmaceutical solid dosage form comprises, by weight of the solid dosage form: (a) 15% to 50% of a solid dispersion comprising the compound of Formula (I) and HMPCAS; (b) 20% to 50% of the microcrystalline cellulose; (c) 20% to 40% of a mannitol; (d) 1.0% to 5.0% of a croscarmellose sodium; and (e) 0.25% to 1.25% of magnesium stearate.